B of A Securities Upgrades Revolution Medicines to Buy, Announces $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Alec Stranahan has upgraded Revolution Medicines (NASDAQ:RVMD) from Neutral to Buy and set a price target of $34.

January 05, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revolution Medicines was upgraded by B of A Securities from Neutral to Buy with a price target of $34, indicating a positive outlook on the stock.
Upgrades by analysts, especially from neutral to buy, typically suggest a positive change in the company's fundamentals or prospects, leading to increased investor confidence and potential stock price appreciation. The announcement of a $34 price target further implies a significant upside from the current trading price, which can attract more buyers into the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100